Client: German pharma leader
Customer insight | Go-to-market strategy | Healthcare, medtech & pharma | Asia-Pacific
Client benefit
Informed by our targeted in-depth interviews in five Southeast Asian markets with pulmonologists and rheumatologists treating patients with various types of interstitial lung disease, we recommended priorities for an alternative drug launch, institution-level and physician-level targeting, efficacy messaging, clinician education, and testing/monitoring data.
What we did
For a Germany-based global pharmaceutical drug development leader, seeking new markets for an established product:
- Identified, qualified and interviewed rheumatologists and pulmonologists
- Assessed the market opportunity for an alternative to immunosuppressants
- Mapped diagnosis, patient journey, treatments, management and disease progress monitoring
- Explored the rationales for drugs prescribed and treatment timeframes
- Established significance of reimbursement and levels of price sensitivity
- Tested physicians' perceptions of the new alternative drug profile
- Advised on market opportunities, country priorities and marketing positioning
Find out more
Visit the Healthcare, Medtech & Pharma practice:
Email the Healthcare, Medtech & Pharma practice